NCT07124195View on ClinicalTrials.gov

Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

August 10, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

December 31, 2026

Conditions
Malignant Solid TumorsModerate to High Emetogenic Chemotherapy (MEC/HEC) Drugs
Interventions
DRUG

Medroxyprogesterone acetate oral suspension

Medroxyprogesterone acetate oral suspension (Meishiya®) (administered from Day 1 to 21, 5 ml, once daily)

COMBINATION_PRODUCT

high antiemetic regimen

Ondansetron Injection (administered on Day 1, 8 mg, once daily), Dexamethasone Tablets (administered on Day 1, 12 mg, once daily; administered from Day 2 to 4, 3.75 mg, twice daily), Fosaprepitant (administered on Day 1, 150 mg, once daily)

COMBINATION_PRODUCT

moderate antiemetic regimen

Ondansetron Injection (administered on Day 1, 8 mg, once daily), Dexamethasone Tablets (administered on Day 1, 12 mg, once daily; administered from Day 2 to 4, 3.75 mg, twice daily)

Trial Locations (1)

453100

The First Affiliated Hospital of Xinxiang Medical University, Xinxiang

All Listed Sponsors
lead

The First Affiliated Hospital of Xinxiang Medical College

OTHER